Muscarinic antagonists

Last updated: September 12, 2024

Muscarinic antagonists

FOR MAY EXAM 4M 03/18

FOR MAY EXAM 4M 03/18

Disorders of fatty acid metabolism: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Pyramidal and extrapyramidal tracts
Ascending and descending spinal tracts
Muscle spindles and golgi tendon organs
Somatosensory pathways
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Heparin-induced thrombocytopenia
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Opioid antagonists
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Opioid agonists, mixed agonist-antagonists and partial agonists
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Adrenergic antagonists: Beta blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Cardiac conduction system
Cardiac conduction velocity
ECG basics
ECG rate and rhythm
ECG intervals
ECG QRS transition
ECG axis
ECG normal sinus rhythm
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Extrinsic hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Premature ventricular contraction
Premature atrial contraction
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Atrioventricular block
Bundle branch block
Long QT syndrome and Torsade de pointes
Ventricular tachycardia
Brugada syndrome
Ventricular fibrillation
Pulseless electrical activity
ECG cardiac hypertrophy and enlargement
ECG cardiac infarction and ischemia
Electrolyte disturbances: Pathology review
Postoperative evaluation: Clinical
Mesothelioma
Lung cancer and mesothelioma: Pathology review
Diffuse parenchymal lung disease: Clinical
Lung cancer: Clinical
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Restrictive lung diseases: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Arsenic poisoning
Cyanide poisoning
Lead poisoning
Methemoglobinemia
Ethylene glycol poisoning
Mercury poisoning
Paracetamol toxicity
Serotonin syndrome
Neuroleptic malignant syndrome
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Pneumothorax
Pneumothorax: Clinical
Chest trauma: Clinical
Pleural effusion: Clinical
Ehlers-Danlos syndrome
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Thoracic wall
Anatomy clinical correlates: Pleura and lungs
Anatomy clinical correlates: Mediastinum
Shock: Clinical

Flashcards

Muscarinic antagonists

0 of 23 complete

Questions

USMLE® Step 2 style questions USMLE

0 of 6 complete

A 65-year-old man comes to the emergency department during the winter due to shortness of breath and a productive cough. The symptoms have progressively worsened over the past two years, and the patient has had to limit his daily activities to avoid becoming short of breath. Each morning, he coughs up large quantities of viscous sputum. Past medical history is significant for hypertension and type II diabetes mellitus. Current medications include lisinopril and metformin. Temperature is 36.4°C (97.6°F), pulse is 120/min, respirations are 24/min, and blood pressure is 147/98 mmHg. Oxygen saturation is 93% on room air. Physical examination reveals a markedly increased anteroposterior chest diameter. Cardiopulmonary examination reveals tachycardia and poor air movement bilaterally with scattered expiratory wheezes. A chest radiograph is obtained and shown below. Which of the following medications is most appropriate for managing this patient’s symptoms?  


Image reproduced from Radiopedia

Transcript

Watch video only

Muscarinic antagonists, or antimuscarinic medications, are a class of medications that prevent muscarinic receptors of the parasympathetic nervous system from getting stimulated by acetylcholine.

Okay, first things first, the nervous system is divided into the central nervous system, so the brain and spinal cord; and the peripheral nervous system.

The peripheral nervous system can be divided into the somatic nervous system, which controls voluntary movement of our skeletal muscles; and the autonomic nervous system, which is further divided into the sympathetic and parasympathetic nervous systems, and controls the involuntary movement of the smooth muscles, and the glands of our organs.

Now, the autonomic nervous system is made up of a relay that includes two neurons.

We’ll focus on just the parasympathetic nervous system.

Signals for the parasympathetic nervous system start in the hypothalamus.

These hypothalamic neurons synapse with nuclei in the brainstem or spinal cord, which send out signals to preganglionic neurons that travel to the rest of the body.

Their targets are the parasympathetic ganglion, which consist of many postganglionic neuron cell bodies and are located nearby or directly in the target organs.

The postganglionic neurons extend the rest of the way to the target cell, where they release the neurotransmitter acetylcholine, which is why they are also called cholinergic neurons.

Acetylcholine binds to a type of receptor, known as muscarinic receptors, on the cells of target organs, which allow the parasympathetic nervous system to trigger a ‘rest and digest’ response, meaning that it keeps body-energy use as low as possible to stimulate activities like digestion.

It acts in the heart, slowing the heart rate and reducing the cardiac output.

In the gastrointestinal tract, it increases its motility to stimulate digestion and defecation.

In the bladder, it causes constriction of the bladder muscle, called the detrusor muscle, which stimulates urination.

In salivary, sweat, and lacrimal glands, it increases their secretions.

In the liver, it triggers glucose storage to reduce blood glucose levels.

In the lungs, it causes bronchoconstriction, since in a relaxed state our cells do not consume as much oxygen.

In the eyes, it triggers miosis, or constriction of the pupils, to improve close vision and stimulates the contraction of the ciliary muscles, increasing the outflow of aqueous humor, which is the fluid in the anterior chamber of the eye, and this decreases the intraocular pressure.

Finally, its effects on the brain are extremely complicated, but generally, they cause overall stimulation, and they participate in many wanted and unwanted functions, such as movement control and vomiting, respectively.

Alright, so medications that block the effects of acetylcholine on muscarinic receptors are called muscarinic antagonists or antimuscarinic medications.

Now, the most famous muscarinic antagonist is atropine.

Atropine blocks the “rest and digest” effect from the parasympathetic system, so clinically, it can be used to treat bradycardia, or slowed heart rate.

It decreases bladder smooth muscle contraction so it’s useful for preventing nocturnal enuresis, or bedwetting, in children.

Ophthalmologists can also use atropine to dilate the pupils.

Finally, it’s an antidote for poisoning by anticholinesterases like organophosphates found in pesticides. These agents prolong the effect of acetylcholine by inhibiting their break down, so atropine can help by simply blocking the muscarinic receptors.

Now, for side effects, atropine can produce: tachycardia, or increased heart rate; constipation and urinary retention; dry mouth, skin and eyes; and blurry vision.

The more severe side effects include hyperthermia, dizziness, confusion, and delirium.

It’s also contraindicated in individuals suffering from narrow angle glaucoma since it can worsen the obstruction of aqueous humor drainage.

Key Takeaways

Muscarinic antagonists, also known as antimuscarinic medications, are a class of drugs that block the activation of muscarinic receptors of the parasympathetic nervous system. Examples of muscarinic antagonists include atropine, scopolamine, and ipratropium. These drugs are used to treat a variety of conditions, such as asthma, glaucoma, and urinary incontinence. They can also be used to treat the symptoms of poisoning from organophosphate insecticides.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Muscarinic receptor subtypes in airways" Life Sci (1993)
  5. "Pharmacologic therapy of obstructive airway disease" Clin Chest Med (1990)
  6. "[Atropine. Principles and rules of utilization]" Rev Prat (2001)
  7. "Antimuscarinic drugs" Prof Nurse (2004)